 |
|
Epoetin Alfa for the Treatment of the Anemia of Multiple MyelomaA Prospective, Randomized, Placebo-Controlled, Double-blind Trial
John P. Garton, MD;
Morie A. Gertz, MD;
Thomas E. Witzig, MD;
Philip R. Greipp, MD;
John A. Lust, MD;
Georgene Schroeder, MS;
Robert A. Kyle, MD
Arch Intern Med. 1995;155(19):2069-2074.
Abstract
Background
To determine the efficacy of epoetin alfa for the treatment of the anemia of multiple myeloma, a prospective, randomized, placebo-controlled, double-blind clinical trial enrolled 25 patients with the anemia of multiple myeloma and a hematocrit less than 0.30.
Methods
Epoetin alfa, 150 U/kg, or a matching volume of placebo was administered subcutaneously three times per week for 6 weeks. If the criterion for a response was not met, the dose was doubled. After 12 weeks, nonresponders in the placebo arm were switched to an open-label study of epoetin alfa at a dose of 150 U/kg for 6 weeks. After 6 weeks, the dose was doubled if no response was obtained. A partial response was defined as an increase of 6 percentage points or greater in the hematocrit without transfusion. A complete response required a final hematocrit of 0.38 or greater without transfusion. Complete responders had reduction of epoetin alfa to the lowest dose capable of maintaining the complete response.
Results
Twenty patients were evaluable for response to therapy. During the double-blind phase, six patients who were receiving epoetin alfa had a complete response, one had a partial response, and three were nonresponders. No responses occurred in the placebo arm. In the open-label phase, of the 10 patients who were originally receiving placebo, three had a complete response, one had a partial response, and six were nonresponders. Chemotherapy, pretreatment serum erythropoietin levels, disease duration, and reticulocyte count did not predict the response to epoetin alfa. The median final dose for the responding group was 120 U/kg three times per week to maintain a hematocrit greater than 0.38. There was no effect on the course of the myeloma, and no hypertension was seen.
Conclusion
Treatment with epoetin alfa is effective and safe in patients with the anemia of multiple myeloma.
(Arch Intern Med. 1995;155:2069-2074)
Author Affiliations
From the Division of Hematology and Internal Medicine (Drs Garton, Gertz, Witzig, Greipp, Lust, and Kyle) and the Cancer Center Statistics Unit (Ms Schroeder), Mayo Clinic and Mayo Foundation, Rochester, Minn.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns
Stasi et al.
The Oncologist 2005;10:539-554.
ABSTRACT
| FULL TEXT
Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
Witzig et al.
JCO 2005;23:2606-2617.
ABSTRACT
| FULL TEXT
rHuEPO and Treatment Outcomes: The Preclinical Experience
Ludwig
The Oncologist 2004;9:48-54.
ABSTRACT
| FULL TEXT
Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine
Henry et al.
Arch Intern Med 2004;164:262-276.
ABSTRACT
| FULL TEXT
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology
Rizzo et al.
JCO 2002;20:4083-4107.
ABSTRACT
| FULL TEXT
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
Rizzo et al.
Blood 2002;100:2303-2320.
ABSTRACT
| FULL TEXT
Update on the Treatment of Multiple Myeloma
Kyle
The Oncologist 2001;6:119-124.
ABSTRACT
| FULL TEXT
Use of Recombinant Human Erythropoietin Outside the Setting of Uremia
Cazzola et al.
Blood 1997;89:4248-4267.
FULL TEXT
Multiple Myeloma: An Overview in 1996
Kyle
The Oncologist 1996;1:315-323.
ABSTRACT
| FULL TEXT
EPOETIN ALFA FOR ANEMIA OF MULTIPLE MYELOMA
JWatch General 1995;1995:7-7.
FULL TEXT
|
